MX2022006892A - Compuesto agonista del receptor sensor de calcio y aplicación del mismo. - Google Patents

Compuesto agonista del receptor sensor de calcio y aplicación del mismo.

Info

Publication number
MX2022006892A
MX2022006892A MX2022006892A MX2022006892A MX2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A MX 2022006892 A MX2022006892 A MX 2022006892A
Authority
MX
Mexico
Prior art keywords
calcium
application
sensing receptor
agonist compound
receptor agonist
Prior art date
Application number
MX2022006892A
Other languages
English (en)
Inventor
Jin Zhang
Lei Wang
Fei Gao
Cheng Liao
Fangzhou Wu
Ran Wu
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of MX2022006892A publication Critical patent/MX2022006892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se proporciona un compuesto agonista del receptor sensible al calcio (CaSR) y su aplicación. Específicamente, se proporcionan una serie de compuestos agonistas de CaSR polipeptídicos y sales farmacéuticamente aceptables de los mismos, que tienen efectos agonistas en los CaSR humanos para reducir los niveles de hormona paratiroidea en plasma y de iones de calcio en suero, y pueden usarse para el tratamiento de enfermedades metabólicas tales como hiperparatiroidismo primario, hiperparatiroidismo secundario. hiperparatiroidismo e hipercalcemia inducida por tumores.
MX2022006892A 2019-12-09 2020-12-08 Compuesto agonista del receptor sensor de calcio y aplicación del mismo. MX2022006892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
MX2022006892A true MX2022006892A (es) 2022-10-07

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006892A MX2022006892A (es) 2019-12-09 2020-12-08 Compuesto agonista del receptor sensor de calcio y aplicación del mismo.

Country Status (11)

Country Link
US (1) US20230041996A1 (es)
EP (1) EP4091623A4 (es)
JP (1) JP2023504904A (es)
KR (1) KR20220110789A (es)
CN (1) CN114222578A (es)
AU (1) AU2020399030A1 (es)
BR (1) BR112022011127A2 (es)
CA (1) CA3159744A1 (es)
MX (1) MX2022006892A (es)
TW (1) TW202122410A (es)
WO (1) WO2021115272A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4353248A1 (en) 2021-06-08 2024-04-17 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Calcium-sensing receptor agonist composition and application thereof
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1619180B1 (en) * 2003-04-23 2009-12-16 Japan Tobacco Inc. CaSR ANTAGONIST
PL3192520T3 (pl) * 2009-07-29 2019-08-30 Kai Pharmaceuticals, Inc. Środki lecznicze do zmniejszania poziomów parathormonu
RU2013128973A (ru) * 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
JP2014508103A (ja) * 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
BR112013031539A2 (pt) * 2011-06-08 2019-07-30 Kai Pharmaceuticals Inc agentes terapêuticos para regular fósforo sérico
AU2012335009B2 (en) * 2011-11-10 2017-08-31 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use

Also Published As

Publication number Publication date
JP2023504904A (ja) 2023-02-07
US20230041996A1 (en) 2023-02-09
TW202122410A (zh) 2021-06-16
KR20220110789A (ko) 2022-08-09
CA3159744A1 (en) 2021-06-17
BR112022011127A2 (pt) 2022-08-23
AU2020399030A1 (en) 2022-06-23
EP4091623A1 (en) 2022-11-23
WO2021115272A1 (zh) 2021-06-17
CN114222578A (zh) 2022-03-22
EP4091623A4 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
MX2022006892A (es) Compuesto agonista del receptor sensor de calcio y aplicación del mismo.
PH12020551066A1 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JOP20190229B1 (ar) مركبات تثبط بروتين mcl-1
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
EP3952902A4 (en) DOSAGE FORMS AND TREATMENT SCHEMES FOR AMINO ACID COMPOUNDS
ZA202202097B (en) Amino pyrimidine ssao inhibitors
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
CL2021003017S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
NZ703347A (en) Use of 2-methylene-19-nor-(20s)-1α,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
MX2020002430A (es) Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1).
MX2022005813A (es) Formas de dosificacion novedosas de rofecoxib y métodos relacionados.
EP2582240A4 (en) HERBICIDE COMPOSITION BASED ON PICOLINIC ACID SALT
CL2020001420A1 (es) Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil] amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico.
MX2018012224A (es) Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
Vestergaard Medical treatment of primary, secondary, and tertiary hyperparathyroidism
WO2006113990B1 (en) LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
MX2019014201A (es) Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
MX2021010596A (es) Composicion farmaceutica que contiene oseltamivir.
IL290927A (en) The composition used to combat metabolic diseases and uses of the composition
MX2018013410A (es) Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.